ProteoGenix, Aseem Healthcare, and Trident Biopharm Solutions Announce a New Antibody Cocktail Effective Against Major Variants of SARS-CoV-2
Schiltigheim, France – 7 June 2022 – Life Science Newswire –
ProteoGenix (market-leading antibody provider), Aseem Healthcare (global
healthcare company), and Trident Biopharm Solutions (life science
consultancy agency) are pleased to announce the development of a new
antibody cocktail effective against major variants of SARS-CoV-2. The
cocktail of four fully human neutralizing antibodies (AH-5-COV) was
generated by screening the plasma of a COVID-19 survivor using
ProteoGenixís phage display platform. The new treatment is undergoing
preclinical evaluation and will be ready to start clinical trials in 2
months.
